SecBot SecBot
6-K ·Filed May 14, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001654954-26-004836
Notable filing: 6-K
Actionable Insight ▲ Bullish

The VOLGA data significantly strengthens Imfinzi's franchise in bladder cancer and opens a new large patient segment. Traders should watch for regulatory submissions (US, EU, Japan) and potential label expansion over the next 12-18 months, which could drive consensus revenue upgrades for AZN. Near-term, the stock may see a positive reaction as the market prices in this pipeline de-risking.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$185.01
T+0 close · May 14, 2026 · via day close
Latest settled
−12.65%
T+60 · $161.61
Vs SPY
−15.97%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 14 $185.01entry
  2. T+1 · 6mo ago −1.89%α −0.66% · $181.52
  3. T+5 · 6mo ago +2.57%α +3.28% · $189.76
  4. T+20 · 5mo ago −3.38%α −2.52% · $178.75
  5. T+60 · 3mo ago −12.65%α −15.97% · $161.61

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced positive Phase III VOLGA trial results showing that perioperative Imfinzi (durvalumab) plus neoadjuvant enfortumab vedotin (EV) achieved statistically significant and clinically meaningful improvements in both event-free survival (EFS) and overall survival (OS) in cisplatin-ineligible or -declining muscle-invasive bladder cancer (MIBC) patients versus standard of care (radical cystectomy). This is the third positive bladder cancer readout for Imfinzi, reinforcing its position as an immunotherapy backbone in early-stage, curative-intent bladder cancer and expanding its addressable market to a large underserved population (up to 50% of MIBC patients who cannot receive cisplatin).

Key Facts

  • Perioperative Imfinzi + neoadjuvant EV showed statistically significant and clinically meaningful improvements in both EFS and OS in MIBC patients ineligible for or declining cisplatin.
  • The Imfinzi + Imjudo + EV arm showed statistically significant EFS improvement and a favorable OS trend, but OS was not statistically significant at this interim analysis.
  • This is the third positive Phase III bladder cancer readout for Imfinzi (after NIAGARA and POTOMAC), establishing it as the immunotherapy backbone in early-stage bladder cancer.
  • Approximately 50% of MIBC patients are ineligible for cisplatin, representing a large underserved population; the VOLGA regimen addresses this unmet need.
  • Safety profiles were consistent with known profiles of individual medicines; no new safety signals identified.
  • Data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
  • Imfinzi is already approved in over 40 countries for cisplatin-eligible MIBC based on the NIAGARA trial.

Financial Impact

Expands Imfinzi's addressable MIBC market by up to ~50% (cisplatin-ineligible patients); potential peak sales contribution in the hundreds of millions to low billions annually, given bladder cancer is the 9th most common cancer globally with >614,000 cases/year.

revenuemarket share

Risk Factors

  • Regulatory timelines and approval decisions are uncertain; any delays or rejections would dampen the upside.
  • Competition from other PD-(L)1 inhibitors and antibody-drug conjugates (e.g., Keytruda, Padcev) could limit market share.
  • The OS benefit in the Imfinzi + Imjudo + EV arm was not statistically significant at this interim analysis, leaving some uncertainty about the optimal combination.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-004836
Document: 0001654954-26-004836-index-headers.html0001654954-26-004836
Document: 0001654954-26-004836-index.html0001654954-26-004836
Document: 0001654954-26-004836.txt0001654954-26-004836

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202611d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Tue (16h 41m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 14, 2026